So my contact form request came back with this response. My French must have been terrible because they wrote it in English!

Anyway http://bekerhepc.com is directly from Beker Laboratoires and Sofosled is a real product.

———- Forwarded message ———-
From: Sofos Hotline
Date: 19 May 2016 at 22:08
Subject: Website Laboratoires Beker & Bekerhepc.com
To: help@fixhepc.com

Dear Sir, Madam,

I am writing to you as per a request that was forwarded to me by our team following a post on your forum.

I wanted to certify to you that the website Bekerhepc.com is part of Laboratoires Beker. I have actually mentioned it to our IT team so that we can link them together so that it will be easier for patients to have access to all information as well as add Sofosled in our drug portfolio as it wasn’t there apaprently.

We are aware that our team members have been posting on patients forum the information about the plateform as it is fairly new.

You can also follow us on twitter @labobeker or on facebook for more information

Please do not hesitate to ask us any questions you might have on us, the plateform, the website or the treatment.

Looking forward to hearing from you!

Kind regards

Beker Team

Dr.Freeman, do you know wich research wich is not published yet is Greg talking about?

Yes, his, mine and other people we know.

SOF+DCV in GT1 is getting really good SVR rates of 95%+ but the same SOF+DCV in GT3 is seeing SVR rates below 90% in the 12 week patients. Looking at the kinetics we see that in GT1 SOF+DCV is as good or better than SOF+LDV, but when we compare SOF+DCV in GT1 and GT3:

Now my interpretation of this graph is that while in GT1 we are reliably at UND by about 55 days (giving a 30 day over-treat) this is not the case in GT3 which decays much slower. This slower decay suggests longer treatment is required if we want the same insurance over-treatment buffer we have in GT1.

The sad reality is that the current DAA agents are worst in GT3, and Ribavirin does not seem to help much (if at all), so in the absence of better what we have for the moment is LONGER (or adding in Interferon and Riba)

I know people don’t like to hear it but for some low fibrosis/low life impact GT3 patients waiting for better agents is a perfectly sane option, as is treating for a bit longer than current guidelines suggest for F0-F2

Hi Kevin,

Thanks for the research. I have asked directly.

Great news Tweakmax…..those results are a carbon copy of mine at SVR12 The time will fly by……

Although the prices are higher than other options it’s good to see the idea of access by personal importation starting to take root.

Hi Simone,

The key questions are Genotype and Fibrosis with Viral load and other medications potentially playing a role.

Do you know these details?

There is a handy decision support tool at http://fixhepc.com/hcv where you can put in some details and it will give you the answers according to various widely accepted guidelines – it’s a kind of inst-a-expert.

Having an online consultation on https://gp2u.com.au/ would let you discuss with a doctor very familiar with the medications.

Hi Bob,

I presume you stopped the Riba because of the sides. It takes 21 days to drop by half so you will have had nearly 6 weeks worth. It’s not something usual, but will certainly have done no harm. Monotherapy with any drug, even Sofosbuvir is a bad idea so don’t take it after treatment.

Given you’ve stopped it I would stay stopped secure in the knowledge you hit the virus hard at the start.